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Abstract
Purpose Pyrrole–imidazole (Py-Im) polyamides are pro-
grammable, sequence-specific DNA minor groove–binding
ligands. Previous work in cell culture has shown that various
polyamides can be used to modulate the transcriptional pro-
grams of oncogenic transcription factors. In this study, two
hairpin polyamides with demonstrated activity against
androgen receptor signaling in cell culture were administered
to mice to characterize their pharmacokinetic properties.
Methods Py-Im polyamides were administered intrave-
nously by tail vein injection. Plasma, urine, and fecal
samples were collected over a 24-h period. Liver, kidney,
and lung samples were collected postmortem. Concentra-
tions of the administered polyamide in the plasma, excre-
tion, and tissue samples were measured using LC/MS/MS.
The biodistribution data were analyzed by both non-com-
partmental and compartmental pharmacokinetic models.
Animal toxicity experiments were also performed by
monitoring weight loss after a single subcutaneous (SC)
injection of either polyamide.
Results The biodistribution profiles of both compounds
exhibited rapid localization to the liver, kidneys, and lungs
upon injection. Plasma distribution of the two compounds
showed distinct differences in the rate of clearance, the
volume of distribution, and the AUCs. These two com-
pounds also have markedly different toxicities after SC
injection in mice.
Conclusions The variations in pharmacokinetics and
toxicity in vivo stem from a minor chemical modification
that is also correlated with differing potency in cell culture.
The results obtained in this study could provide a structural
basis for further improvement of polyamide activity both in
cell culture and in animal models.
Keywords Py-Im polyamides  Pharmacokinetics 
Toxicity  Biodistribution  Mice
Introduction
The development of new DNA-targeted therapeutics is a
promising frontier in the treatment of human disease.
Pyrrole–imidazole (Py-Im) polyamides are peptides of
cyclic aromatic amino acids whose anti-parallel pairing
confers sequence-specific binding to the DNA minor
groove [1–4]. Members of this class of compounds have
been used to modulate gene expression programs in cell
culture [5–13] and affect tumor growth in animal models
[14–16].
Recently, a series of Py-Im polyamides have been
developed to disrupt androgen receptor (AR) signaling [5,
6, 11], presenting an alternative strategy for therapeutic
intervention in prostate cancer. These compounds were
designed to bind to a 50-WGWWCW-30 sequence con-
tained within the consensus androgen response element
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(ARE) to prevent AR protein–DNA interactions. Cell cul-
ture experiments of LNCaP prostate cancer cells co-treated
with dihydrotestosterone (DHT) and ARE-targeted polya-
mides have shown decreased expression of several AR-
driven genes such as PSA, KLK2, and TMPRSS2 when
compared to samples treated with DHT alone. Polyamide 1
inhibited DHT-induced genes in a dose-dependent manner
ranging from 0.74 to 7.4 lg/mL, with 7.4 lg/mL being the
most active concentration [11]. Polyamide 2 contains a
minor structural modification where the (R)-2,4-diamin-
obutyric acid turn of 1 is replaced with an acetylated (R)-
3,4-diaminobutyric acid. Due to this modification, poly-
amide 2 was found to have equivalent activity to 1 at
tenfold less concentration without significant changes to its
DNA-binding ability [6, 8, 11].
While the pharmacokinetics of other Py-Im polyamides
have been published previously [17–20], the PK profiles of
these structurally distinct ARE-targeted hairpin polyamides
have never been explored. For this study, mice were chosen
as the preclinical model for the determination of polyamide
concentrations in plasma, liver, kidney, and lung. In addi-
tion, urinary and fecal levels were measured to assess the
relative importance of these routes of drug elimination. The
data presented here represent the first detailed description
of the in vivo pharmacokinetic and toxicological study of
these molecules.
Materials and methods
Chemicals and reagents
Acetonitrile (ACN) and methanol (MeOH) were of HPLC
grade and purchased from Fisher Scientific (Fair Lawn, NJ,
USA). Glacial acetic acid (ACS grade) was purchased from
J. T. Baker (Phillipsburg, NJ, USA). Formic acid (99 %
pure) was from Acros Organic (New Jersey, USA). Water
was purified using the Millipore Milli-Q system (Milford,
MA, USA). Mouse plasma for preparation of standards and
quality controls (QC) was obtained from The City of Hope
Medical Center Animal Center. Py-Im polyamides 1–4
were synthesized by solid-phase synthesis as previously
described [21, 22]. For structures of internal standards
(INS) 3 and 4, see Online Resource Fig. S1.
Animals for pharmacokinetic studies
Pyrrole–imidazole polyamide pharmacokinetic studies
were performed in 10- to 12-week-old female BALB/C
mice (Charles River). Polyamides were solubilized in PBS
(1) or PBS/DMSO (2) and administered via intravenous
(IV) tail vein injection at concentrations of 7.5 and 5 mg/kg,
respectively. For each experiment, groups of 3 animals
were euthanized at 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 h
after injection. Animals designated for the 4, 8, and 24 h
time points were housed in metabolic cages for collection
of urine and feces as described below. All animals used in
the pharmacokinetic experiments were performed under an
approved protocol at the City of Hope.
Animals for toxicology studies
Toxicities of polyamides 1 and 2 were measured after SC
injections in 8- to 12-week-old female C57BL/6 mice
(Jackson Laboratory). In anticipation of future xenograft
experiments, subcutaneous injection, which has been
shown to be a viable route of polyamide delivery [20], was
chosen as the desired delivery method. A single bolus of
polyamide 1 or 2 in PBS/DMSO vehicle was given, and the
animals were weighed daily and monitored closely for
signs of duress for 7 days. Animals exhibiting [15 %
weight loss or signs of distress were euthanized according
to regulations outlined by IACUC. Four animals were used
in each group unless otherwise noted. This toxicology
study was performed under an approved protocol at the
California Institute of Technology.
Analytical methods development
Concentrations of polyamides 1 and 2 were analyzed
by LC/MS/MS using a Waters Acquity UPLC system
(Milford, MA, USA) interfaced with a Waters Quattro
Premier XE Mass Spectrometer. HPLC separation was
achieved using a Jupiter 4u Proteo 90A 150 9 2.0 mm
column (Phenomenex, Torrance, CA, USA) proceeded by a
Phenomenex C8 guard column (Torrance, CA, USA). The
column temperature was maintained at 30 C. The mobile
phase consisted of A (0.05 % acetic acid in water) and B
(0.05 % acetic acid in acetonitrile). The following gradient
program was used: 8 % B (0–1 min, 0.3 ml/min), 16 % B
(3 min, 0.3 ml/min), 58 % B (6 min, 0.3 ml/min), 90 % B
(7 min, 0.3 ml/min), and 8 % B (7.3 min, 0.3 ml/min). The
total run time was 11.5 min. The auto-injector temperature
was maintained at 5 C. The strong needle wash solution
was 5 % formic acid in MeOH/ACN (2:8) for both com-
pounds, and the weak needle wash solution was 30 %
MeOH in water for compound 1 and 50 % ACN in water
for compound 2. The electrospray ionization source of the
mass spectrometer was operated in positive ion mode with
a cone gas flow of 50 L/hr and a desolvation gas flow of
700 L/hr. The capillary voltage was set to 3.2 kV, and the
cone and collision cell voltages were optimized to 32 and
27 V for 1 and the INS 3. Voltages were optimized to 31
and 20 V for 2 and the INS 4. The source temperature was
125 C, and the desolvation temperature was 470 C. A
solvent delay program was used from 0 to 4.0 min and
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from 6.1 to 11.5 min to minimize the mobile phase to flow
to the source. MassLynx version 4.1 software was used for
data acquisition and processing.
Positive electrospray ionization of all compounds pro-
duced abundant protonated molecular ions (M ? 3H) 3?.
The fragmentations of these compounds were induced
under collision-induced dissociation condition. The precur-
sor ? product ion combinations at m/z 453.52 ? 206.10
for 1, 454.85 ? 210.24 for 3, 467.45 ? 238.32 for 2, and
469.9 ? 238.4 for 4 were used in multiple reaction moni-
toring (MRM) mode for determination of these com-
pounds. The use of MRM provided sufficient specificity
and sensitivity. MS/MS experimental conditions, such as
collision energy and collision cell pressure, were opti-
mized from continuous flow injection sample introduction
of standard solutions. Under optimized assay conditions,
the retention times for 1 and 3 were 5.0 min, and 5.5 min
for 2 and 4.
Plasma sample preparation
Plasma and urine samples were prepared for LC/MS/MS
analysis by mixing 30 lL of plasma with 20 lL of 50 %
MeOH and 50 % aqueous 1 % HOAc. The mixture was
vortexed and mixed with an additional 120 lL of 0.5 %
HOAc in MeOH/ACN (4:6) and 20 lL of 6.0 lg/mL
INS in MeOH/1 % aqueous HOAc (1:1). The mixture
was vortexed again for 2 min and centrifuged at the
highest setting for 4 min. Next, 20 lL of the superna-
tant was transferred to a new tube and mixed with
180 lL of 50 % MeOH/ACN (4:6) and 50 % aqueous
1 % HOAc.
Standard curves were prepared mixing untreated plasma
with 20 lL of 50 % MeOH and 50 % aqueous 1 % HOAc
prepared with various concentrations of 1 and 2. Internal
standards were added as described above. The standard
curves, as determined by linear regression, displayed good
linearity (r2 [0.99) over the range tested for 1 (0.1–30 lg/mL)
and 2 (0.2–20 lg/mL).
Urine and fecal sample preparation
Urine and fecal samples were collected using metabolic
cages (Ancare, Techniplast Metabolic Rack, 12 cages by
Nalgene). Urine samples were collected at 3 time points
over 24 h, and fecal samples were collected at 8 and 24 h
time points. Py-Im polyamides were extracted from urine
according to the plasma extraction procedure described
above.
Fecal samples were first dried at room temperature and
then weighed and grounded to a powder. Approximately
100 mg of powder was weighed out and reconstituted in
distilled water (6 lL/mg powder). The fecal sample was
then homogenized in a TissueLyser (Qiagen) for 2 min at
30 Hz twice, and an additional 6 lL/mg of distilled water
was added. Next, 30 lL of the fecal homogenate was
mixed with 50 lL distilled water and 20 lL of 50 %
MeOH and 50 % aqueous 1 % HOAc. The mixture was
then vortex mixed with 0.1 mL 0.5 % HOAc in MeOH/
ACN (2:8) and 20 lL of 6.0 lg/mL INS in MeOH/1 %
aqueous HOAc (1:1) for 10 min and centrifuged at the
highest setting for an additional 10 min. The supernatant
was diluted with 50 % MeOH/ACN (4:6) and 50 %
aqueous 1 % HOAc.
Tissue sample preparation
Distribution of polyamides 1 and 2 was determined in the
liver, kidneys, and lungs. The organs were harvested post-
euthanasia and prepared via similar processes. A piece of
the mouse organ was weighed and mixed with distilled
water (3 lL/mg tissue). The tissue was then homogenized
by pulsing three times on a TissueLyser for 2 min each at
30 Hz. Next, 30 lL of the tissue homogenate was mixed
with 20 lL of 50 % MeOH and 50 % aqueous 1 %
HOAc. The mixture was then vortex mixed with 0.12 mL
0.5 % HOAc in MeOH/ACN (2:8) and 20 lL of 6.0 lg/mL
INS in MeOH/1 % aqueous HOAc (1:1) for 10 min and
centrifuged at the highest setting for an additional
10 min. Samples treated with polyamide 1 were then
diluted with 50 % MeOH/ACN (4:6) and 50 % aqueous
1 % HOAc. Samples treated with polyamide 2 were
diluted with 50 % MeOH/ACN (4:6) and 50 % aqueous
3 % FA.
Pharmacokinetic data analysis
Plasma pharmacokinetic parameters were derived from
polyamide concentration profiles using both non-compart-
mental and compartmental methods. Non-compartmental
analysis was performed according to statistical moment
theory and the rule of linear trapezoids, while compart-
mental analysis was performed in ADAPT II [24]. Pharma-
cokinetic parameters estimated from the non-compartmental
analysis include the maximum concentration (Cmax), the
terminal elimination half-life (t1/2), the mean residence
time (MRT), the area under the concentration curve
(AUC0–24h), the AUC extrapolated to infinity (AUC0–?),
and the clearance (CL). Additional plasma pharmacoki-
netic parameters determined from the compartmental
analysis include the alpha and beta half-lives (t1/2) and the
apparent volume of distribution (Vd). Tissue pharmacoki-
netic parameters were determined non-compartmentally
and included the Cmax and AUC0–24h. Urinary and fecal
excretion data were expressed as the cumulative percentage
of the administered dose.
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pH stability analysis
The pH stability of Py-Im polyamides was analyzed as
previously described [23]. In summary, 15 lL of a 10 lM
solution of polyamide 1 or 2 in DMSO was incubated with
85 lL of buffer with pH of 2.5, 4, 7, or 10 (Fluka) at 37 C
for 24 h. After incubation, the sample was mixed with an
equal volume of N,N-dimethylformamide and sonicated
briefly. Next, 20 lL of the sample solution was mixed with
180 lL of aqueous buffer containing 100 mM NH4OAc
and 25 lM methyl 4-nitro-1H-pyrrole-2-carboxylate as an
internal standard. Analytical HPLC analysis was performed
on a Beckman analytical HPLC.
Results
Plasma distribution
The structures and plasma concentration profiles of
polyamides 1 and 2 are shown in Fig. 1, and the pharma-
cokinetic parameters calculated non-compartmentally and
using a 2-compartment model are summarized in Table 1.
Plasma concentrations for both polyamides were well
above the lower limit of quantification over the entire time
course. The average Cmax was 49.4 ± 11.2 lg/mL
(mean ± S.D., n = 3) for 1 and 41.3 ± 5.9 lg/mL for 2.
Both compounds exhibited a bi-exponential pattern of
decay with first-order elimination, with initial and terminal
t1/2’s of 0.5 and 4.6 h for 1, and 0.1 and 4.2 h for 2. The
average concentrations of 1 and 2 24 h postinjection were
0.21 ± 0.1 lg/mL and 0.49 ± 0.2 lg/mL, respectively.
Despite using a higher dose, the AUC of 1 was twofold
lower than 2 (67.5 vs 144.8 lg/mL 9 hr). Furthermore, the
Vd of 1 was twofold higher than 2 (8.1 vs 4.0 mL). The
calculated CL of 1 was threefold higher than 2 (2.1 vs
0.7 mL/hr).
Urine and fecal excretion
Concentration profiles of polyamides 1 and 2 in urine are
shown in Fig. 3. The urinary excretion of polyamide 1 was
nearly complete by 4 h, with a cumulative excretion of
5.7 ± 2.9 % of the administered dose. Urinary excretion of
polyamide 2 was much more extensive and continued
throughout the entire time course, with a cumulative uri-
nary excretion at 24 h of 46.0 ± 15.2 % of the adminis-
tered dose.
Fecal recovery at 8 and 24 h did not yield significant
amounts of either polyamide, with cumulative recoveries
after 24 h of less than 5 % of the administered dose (See
Online Resource Fig. S2). This finding is consistent with
previously published results of a similarly sized polyamide
[19].
Tissue distribution
To examine tissue distribution, several organs previously
reported to have polyamide localization were analyzed.
Distribution profiles of polyamides 1 and 2 in the liver are
shown in Fig. 3a. Both compounds localized rapidly to the
liver post-administration. Polyamide 1 reached a maximum
concentration of 11.7 ± 1.3 lg/g at 5 min postinjection.
The concentration of polyamide 2 also peaked 5 min after
injection at a maximum concentration of 43.8 ± 0.7 lg/g.
Both polyamides exhibited higher retention in the liver
tissue than plasma. At the experiment endpoint, 4.8 ±
0.3 lg/g of 1 and 17.4 ± 8.1 lg/g of 2 were found to
remain in the liver. The AUC0–24h of polyamides 1 and 2 in
the liver were 157.7 and 301.3 lg/g 9 hr, respectively.
The localization of 1 and 2 to the liver is consistent with
previously published positron emission tomography (PET)
results of a related radiolabeled hairpin polyamide [23].
Polyamide pharmacokinetic profile in the kidneys is
shown in Fig. 3b. Maximum kidney concentration of both
polyamides was reached 5 min postinjection with an
average Cmax of 27.0 ± 2.9 lg/g and 35.1 ± 2.8 lg/g for
polyamides 1 and 2, respectively. As in liver, the rate of
polyamide elimination from the kidney was slower than
from the plasma, and the AUC0–24h of polyamides 1 and 2
in the kidney was 299.2 and 424.7 lg/g 9 hr, respectively.
The increased concentrations of polyamide 2 relative to 1
in kidney were consistent with its higher rate of urinary
excretion.
Unlike liver and kidney, polyamide concentrations in
the lung peaked at 15 min following injection for both
compounds (Fig. 3c). The Cmax of polyamide 2 in the lung
was greater than 15-fold higher than compound 1, with
maximum concentrations of 256 ± 93.1 lg/g for 2 and
16.4 ± 1.4 lg/g for 1. After an initial rapid decline,
especially for polyamide 2, concentrations in the lung were
maintained above 2.8 ± 0.2 lg/g and 21.8 ± 7.6 lg/g for
1 and 2, respectively over the entire time course. The
AUC0–24h of polyamides 1 and 2 in the lung was 130.6 and
523.5 lg/g 9 hr, respectively. Tissue PK parameters are
summarized in Table 2.
Compound stability
The stability of polyamides 1 and 2 at various physiolog-
ical pHs was explored by incubating in pH 2.5, 4, 7, and 10
buffers at 37 C for 24 h. Analytical HPLC analysis of
incubated samples did not display significant signs of
degradation at any pH. See Online Resource Fig. S3.
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Toxicity study
Based on a defined threshold of greater than 15 % weight
loss over a 7-day observation period, the toxicity following
a single subcutaneous injection of polyamide 1 or 2 was
determined to be significantly different (Fig. 4). For poly-
amide 1, critical weight loss occurred only at the highest
dose level 10 mg/kg. However, polyamide 2 demonstrated
dose-limiting weight loss at both 4.5 and 2.3 mg/kg. No
additional signs of duress were observed in the animals
treated with polyamide 1; however, animals treated with
polyamide 2 at doses of 4.5 and 2.3 mg/kg exhibited
multiple signs of duress such as loss of ambulation and
hunched posture in addition to weight loss.
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Discussion
Pyrrole–imidazole polyamides are sequence-specific DNA
minor groove binders that have been shown to modulate
gene expression regulated by transcription factors of
oncological importance [10–13]. Of these compounds, two
hairpin polyamides developed to disrupt AR signaling are
of particular interest due to their gene regulation activities
[6, 11] and potent cytotoxicity toward the LNCaP prostate
cancer cell line [25]. While the two hairpin polyamides are
structurally similar, a minor structural modification on the
diaminobutyric acid turn was able to confer a tenfold
increase in the ability of polyamide 2 to downregulate PSA
mRNA expression. In this study, pharmacokinetic methods
were employed to explore the differences in circulation,
excretion, and tissue biodistribution of these ARE-targeted
hairpin polyamides in mice.
Polyamide distribution in the plasma showed clearance
profiles indicative of first-order elimination for both com-
pounds (Fig. 1b; Table 1). These data are in line with
published PK results of related polyamides in rats [17].
The maximum plasma concentration for polyamide 1 was
found to be over 3 times the effect dosage for PSA mRNA
downregulation in cell culture, while the Cmax for poly-
amide 2 was found to be approximately 29 times the
effective concentration. Analysis of the plasma PK data
showed that polyamide 2 exhibited a higher systemic
exposure and lower clearance rate than polyamide 1.
Although the plasma clearance of polyamide 1 was
*threefold faster than polyamide 2, it was not significantly
eliminated through the urine or feces. Polyamide 2, how-
ever, was largely eliminated through the urine (Fig. 2). The
low amount of renal and biliary elimination of compound 1
may be suggestive of compound retention in the tissues or
its metabolic degradation. A previous absorption, distri-
bution, metabolism, excretion, and toxicity (ADMET)
study had ascertained that polyamide 2 was resistant to
liver microsomal degradation [5]; however, the microsomal
stability of polyamide 1 was never examined, and thus,
enzymatic degradation could be a route of elimination for
this compound.
Interestingly, tissue analysis of the liver, kidneys, and
lungs showed higher concentrations of polyamide 2 than 1
(Fig. 3; Table 2). The three organs analyzed here have
been previously documented as representative organs of
polyamide localization [17, 23]; however, it is likely that
the compounds were also taken up and retained in other
tissues types, and that similar differences between the
Table 1 Plasma pharmacokinetic parameters of 1 and 2 after a single
IV injection
Parameter Compound
1 2
I. Non-compartmental analysis
mg/kg 7.5 5
Cmax (lg/mL) 49.4 ± 11.2 41.3 ± 5.9
Elimination t1/2 (hr) 5.2 4.3
MRT (hr) 3.3 4.9
AUC0–t (lg/mL 9 hr) 75.8 173.5
AUC0–? (lg/mL 9 hr) 77.4 176.5
CL (mL/hr) 1.8 0.6
II. Compartmental analysis
Cmax (lg/mL) 43.6 40.2
t1/2 a (hr) 0.5 0.1
t1/2 b (hr) 4.6 4.2
Vd (mL) 8.1 4
CL (mL/hr) 2.1 0.7
AUC0–? (lg/mL 9 hr) 67.5 144.8
Table 2 Tissue pharmacokinetic parameters of 1 and 2 after a single IV injection
Compound 1 2
Cmax (lg/g) AUC (lg/g 9 hr) Cmax (lg/g) AUC (lg/g 9 hr)
Liver 11.7 ± 1.3 157.7 43.8 ± 0.7 301.3
Kidney 27.0 ± 2.9 299.2 35.1 ± 2.8 424.7
Lung 16.4 ± 1.4 130.6 256 ± 93.1 523.5
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polyamides may exist in these sites. The differences in
biodistribution between the two compounds may be
attributable to differences in solubility. Polyamide 2 is less
soluble than 1 in aqueous solutions and requires a polar
aprotic cosolvent like DMSO for administration. Because
the initial distribution of polyamide 2 to lung tissue was
more than 15-fold higher than polyamide 1, it is possible
that compound 2 is precipitating out of solution as it
reaches high local concentrations when passing through
the lung immediately after an intravenous injection.
Alternatively, it is possible that polyamide 2 is preferen-
tially taken up and retained by the lung tissue itself. This
phenomenon has been previously described for many drugs
and exogenous compounds, and the lungs have been
demonstrated to have significant effects on the pharmaco-
kinetics of drugs given intravenously [26]. Regardless of
the mechanism of accumulation, once the concentration of
polyamide 2 peaks in the lung, it apparently redistributes
unchanged back into circulation as indicated by a second
peak in the plasma concentration versus time profile.
Therefore, rather than being a site for drug elimination, the
lung is serving as a reservoir for polyamide 2 and merely
delays its release back into the central compartment.
In addition to differences in biodistribution, animal
toxicity studies also revealed major differences between
the two compounds. Weight curve experiments following a
single SC injection of 1 and 2 showed polyamide 2 to be
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more toxic (Fig. 4). Animals treated with 1 only showed
significant weight loss at a dose of 10 mg/kg, and no
additional sign of duress was observed. In contrast, animals
treated with polyamide 2 exhibited additional signs of
physical duress in addition to weight loss at all concen-
trations except 1.1 mg/kg. Taken together, given its greater
potency against the expression of select AR-driven genes
and its higher accumulation in normal tissues, the increased
toxicity of polyamide 2 is likely due to off-target effects in
normal organs. However, an alternative explanation for the
increased toxicity seen with polyamide 2 could also be due
to its relatively poor aqueous solubility. For example, in
tissues where high local concentrations of polyamide 2 are
achieved (i.e., lung), the compound may precipitate in
capillaries, resulting in microinfarctions and ischemic tis-
sue injury.
In conclusion, both polyamides 1 and 2 are bioavailable
in mice after IV tail vein injection, and plasma concen-
tration of both compounds is well above the levels required
for gene regulation in cell culture. Although polyamide 2
exhibited more favorable plasma PK characteristics, with a
higher AUC and slower clearance from plasma, it was
found to be significantly more toxic to the animals. This
study was the first to explore the PK properties of ARE-
targeted hairpin polyamides, and it has revealed how a
minor structural modification can influence the PK and
toxicological properties of polyamides, thus setting the
ground work for future xenograft experiments and pro-
viding a potential route to improve polyamide design for
clinical applications.
Acknowledgments The authors would like to thank the National
Institutes of Health for support (Grant GM02768 and CA033572).
The authors thank Jevgenij Raskatov for helpful discussions.
Conflict of interest None.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Dervan PB, Edelson BS (2003) Recognition of the DNA minor
groove by pyrrole-imidazole polyamides. Curr Opin Struct Biol
13(3):284–299
2. Hsu CF, Phillips JW, Trauger JW, Farkas ME, Belitsky JM,
Heckel A, Olenyuk BZ, Puckett JW, Wang CCC, Dervan PB
(2007) Completion of a programmable DNA-binding small
molecule library. Tetrahedron 63(27):6146–6151
3. Kielkopf CL, White S, Szewczyk JW, Turner JM, Baird EE,
Dervan PB (1998) A structural basis for recognition of AT and
TA base pairs in the minor groove of B-DNA. Science
282(5386):111–115
4. White S, Szewczyk JW, Turner JM, Baird EE, Dervan PB (1998)
Recognition of the four Watson-Crick base pairs in the DNA
minor groove by synthetic ligands. Nature 391(6666):468–471
5. Chenoweth DM, Harki DA, Phillips JW, Dose C, Dervan PB
(2009) Cyclic pyrrole-imidazole polyamides targeted to the
androgen response element. J Am Chem Soc 131(20):7182–7188
6. Dose C, Farkas ME, Chenoweth DM, Dervan PB (2008) Next
generation hairpin polyamides with (R)-3,4-diaminobutyric acid
turn unit. J Am Chem Soc 130(21):6859–6866
7. Matsuda H, Fukuda N, Ueno T, Tahira Y, Ayame H, Zhang W,
Bando T, Sugiyama H, Saito S, Matsumoto K, Mugishima H,
Serie K (2006) Development of gene silencing pyrrole-imidazole
polyamide targeting the TGF-b1 promoter for treatment of pro-
gressive renal diseases. J Am Soc Nephrol 17:422–432
8. Meier JL, Montgomery DC, Dervan PB (2012) Enhancing the
cellular uptake of Py-Im polyamides throught next-generation of
aryl turns. Nucleic Acids Res 40:2345–2356
9. Muzikar KA, Nickols NG, Dervan PB (2009) Repression of
DNA-binding dependent glucocorticoid receptor-mediated gene
expression. Proc Natl Acad Sci USA 106(39):16598–16603
10. Nickols NG, Jacobs CS, Farkas ME, Dervan PB (2007) Modu-
lating hypoxia-inducible transcription by disrupting the HIF-1-
DNA interface. ACS Chem Biol 2(8):561–571
11. Nickols NG, Dervan PB (2007) Suppression of androgen
receptor-mediated gene expression by a sequence-specific DNA-
binding polyamide. Proc Natl Acad Sci USA 104(25):10418–
10423
12. Raskatov JA, Meier JL, Puckett JW, Yang F, Ramakrishnan P,
Dervan PB (2012) Modulation of NF-kappaB-dependent gene
transcription using programmable DNA minor groove binders.
Proc Natl Acad Sci USA 109(4):1023–1028
13. Zhang Y, Sicot G, Cui X, Vogel M, Wuertzer CA, Lezon-Geyda
KA, Wheeler JC, Harki DA, Muzikar KA, Stolper DA, Dervan
PB, Perkins AS (2011) Targeting a DNA binding motif of the
EVI1 protein by a pyrrole-imidazole polyamide. Biochemistry
50(48):10431–10441
14. Dickinson LA, Burnett R, Melander C, Edelson BS, Arora PS,
Dervan PB, Gottesfeld JM (2004) Arresting cancer proliferation
by small-molecule gene regulation. Chem Biol 11:1583–1594
15. Kashiwazaki G, Bando T, Yoshidome T, Masui S, Takagaki T,
Hashiya K, Pandian GN, Yasuoka J, Akiyoshi K, Sugiyama H
(2012) Synthesis and biological properties of highly sequence-
specific-alkylating N-methylpyrrole-N-methylimidazole polyam-
ide conjugates. J Med Chem 55:2057–2066
16. Wang X, Nagase H, Watanabe T, Nobusue H, Suzuki T, Asami
Y, Shinojima Y, Kawashima H, Takagi K, Mishra R, Igarashi J,
Kimura M, Takayama T, Fukuda N, Sugiyama H (2010) Inhibi-
tion of MMP-9 transcription and suppression of tumor metastasis
by pyrrole-imidazole polyamide. Cancer Sci 101:759–766
17. Fukasawa A, Aoyama T, Nagashima T, Fukuda N, Ueno T,
Sugiyama H, Nagase H, Matsumoto Y (2009) Pharmacokinetics
of pyrrole-imidazole polyamides after intravenous administration
in rat. Biopharm Drug Dispos 30(2):81–89
18. Nagashima T, Aoyama T, Fukasawa A, Watabe S, Fukuda N,
Ueno T, Sugiyama H, Nagase H, Matsumoto Y (2009) Deter-
mination of pyrrole-imidazole polyamide in rat plasma by liquid
chromatography-tandem mass spectrometry. J Chromatogr B
Analyt Technol Biomed Life Sci 877(11–12):1070–1076
19. Nagashima T, Aoyama T, Yokoe T, Fukasawa A, Fukuda N,
Ueno T, Sugiyama H, Nagase H, Matsumoto Y (2009) Pharma-
cokinetic modeling and prediction of plasma pyrrole-imidazole
polyamide concentration in rats using simultaneous urinary and
biliary excretion data. Biol Pharm Bull 32(5):921–927
20. Raskatov JA, Hargrove AE, So AY, Dervan PB (2012) Phar-
macokinetics of Py-Im polyamides depend on architecture: cyclic
versus linear. J Am Chem Soc 134(18):7995–7999
624 Cancer Chemother Pharmacol (2012) 70:617–625
123
21. Belitsky JM, Nguyen DH, Wurtz NR, Dervan PB (2002) Solid-
phase synthesis of DNA binding polyamides on oxime resin.
Bioorg Med Chem 10(8):2767–2774
22. Nickols NG, Jacobs CS, Farkas ME, Dervan PB (2007) Improved
nuclear localization of DNA-binding polyamides. Nucleic Acids
Res 35(2):363–370
23. Harki DA, Satyamurthy N, Stout DB, Phelps ME, Dervan PB
(2008) In vivo imaging of pyrrole-imidazole polyamides with
positron emission tomography. Proc Natl Acad Sci USA
105(35):13039–13044
24. D’Argenio DZ, Schumitzky AX, Wang X (2009) ADAPT 5
User’s Guide: pharmacokinetic/pharmacodynamic systems anal-
ysis software. Biomedical Simulations Resource, Los Angeles
25. Jacobs CS, Dervan PB (2009) Modifications at the C-terminus to
improve pyrrole-imidazole polyamide activity in cell culture.
J Med Chem 52:7380–7388
26. Boer F (2003) Drug handling by the lungs. Br J Anaesth
91(1):50–60
Cancer Chemother Pharmacol (2012) 70:617–625 625
123
